EMERYVILLE, CA, Slingshot Biosciences, a biotechnology company, announced the closing of $11 million in a Series A3 financing.
Slingshot Biosciences, a biotechnology company building the world's first on-demand synthetic cell platform for customizing cell and cell line mimics, announced the closing of $11 million in a Series A3 financing.
The investment was co-led by ARCH Venture Partners and, with participation from Anterra Capital.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
